Last reviewed · How we verify
Castration-resistant prostate cancer
Approved treatments
- Erleada · Johnson & Johnson
Erleada blocks the androgen receptor, a protein that helps cancer cells grow.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Castration-resistant prostate cancer patent landscape — cliff calendar, originator estates, attackable patents
- Castration-resistant prostate cancer treatment landscape brief
- Castration-resistant prostate cancer treatment updates RSS
Frequently asked questions about Castration-resistant prostate cancer
What drugs treat Castration-resistant prostate cancer?
Tracked treatments include Erleada.
What is the treatment for Castration-resistant prostate cancer?
Standard treatment for Castration-resistant prostate cancer includes Erleada. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Castration-resistant prostate cancer patent cliff · Castration-resistant prostate cancer CI report
- Treatment: Erleada · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing